Barely Significant
← all excerpts

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.

Front Oncol · 2020 · PMC7028697 · PMID 32117765

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp < 0.0001actually significant
The P -value after day 11 of the treatment remained highly significant (i.e., p < 0.0001) until all mice treated with control ADC, saline and hRS7 were euthanized ( Figure 7A ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.